Compare Gilead Sciences, Inc. (GILD) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Impinj Inc — how do they compare? Gilead Sciences, Inc. trades at $135.97 (market cap $163.51B), while Impinj Inc trades at $137.84 (market cap $4.40B). The key difference: Gilead Sciences, Inc. is far larger — about 37.2× Impinj Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| GILD | PI | |
|---|---|---|
Market Cap | $163.51B | $4.40B |
Sector | Health | Technology |
52-Week High | $155.80 | $241.91 |
52-Week Low | $108.22 | $91.34 |
Enterprise Value | $178.05B | $4.53B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Impinj (PI) trades at $139.54, down 3.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $167.50 implying 20% upside. The company reported Q1 2026 earnings of $0.14 per share, beating estimates, but maintains a negative net income margin of -7.66% for 2025. Recent news highlights insider selling and upcoming Q2 2026 results.
The stock offers growth potential driven by RFID technology leadership and positive earnings surprises, but faces risks from profitability challenges, high valuation multiples, and significant insider selling. Revenue stability contrasts with widening losses, requiring careful monitoring of execution and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
